Envigo Appoints New Director for North American RMS operations
News May 25, 2016
Envigo has announced the appointment of Scott Schulz, MBA, to the post of Director, North American (NA) Operations. In this role, Scott will optimize operational performance and service delivery across the company’s North American based production locations for Research Models and Services (RMS). He will report directly to Michael Caulfield, President North American RMS at Envigo. Scott will serve as the operational leader of the North American Leadership Team.
He has management responsibility for Research Models North American animal production facilities and will drive continuous improvement while ensuring the consistent availability of models to meet customer demand in full. His direction of operational performance will include best-in-class quality, high levels of productivity, animal welfare with a focus on health status and genetics, and fulfilling customer requirements.
Prior to joining Envigo, Scott served as Vice President of Operations at Taconic Biosciences, where he introduced lean manufacturing methodologies including 5S and process mapping and also established a continuous improvement culture through the development of a Lean Six Sigma training programme.
When a Director of Operations at Baxter Health Corporation, Scott led 300 production team members engaged in the manufacture of aseptically filled injectable medication and medical devices for enterprise clients, including major pharmaceutical and biotech companies, and internal customers. Previously, as a senior director of manufacturing operations at Cardinal Health, Scott was responsible for the effective management of a $160 million production operation and over 400 employees.
Commenting on Scott’s appointment, Adrian Hardy at Envigo remarked: “We are delighted that Scott has chosen to join our organisation. With the integration of our products and services across the company now complete, we are increasing our focus on operational excellence. Further optimization of efficiencies and enhancements to processes, operational performance, and service quality to our customers is a paramount objective. We very much look forward to Scott applying his extensive skills and experience towards achieving this across our North American RMS operations.”
Remarking on his appointment, Scott said: “I am very pleased to take on this position and look forward to playing my part in the company’s continued success. I was particularly attracted to Envigo, it is an exciting brand formed through the merger and successful integration of well established companies which provide the market with world class products and services.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE